Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

LCMC study investigators

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)'. Together they form a unique fingerprint.

Medicine & Life Sciences